ArticleGenetics in medicine : official journal of the American College of Medical Genetics2026
The impact of breast cancer polygenic risk score disclosure on decisional conflict around risk-reducing mastectomy in women with pathogenic BRCA1/2 variants.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case report: a rare BRCA1 de novo variant in a female with breast cancer.Hereditary cancer in clinical practice · 2026Article
Corrections and comments
- Update of
Authors and funding
21 authors.
Funding
Abstract
purposeWomen with BRCA1/2 pathogenic variants (PVs) face high breast cancer risks and complex preventive decisions, including whether to undergo risk-reducing mastectomy, which can generate decisional conflict. Polygenic risk scores (PRSs) offer individualized risk estimates that may support informed preventive decisions. We examined whether PRS disclosure reduces decisional conflict about risk-reducing mastectomy in women with BRCA1/2 PVs and whether PRS magnitude interacts with individual characteristics.
methodsUnaffected women with BRCA1/2 PVs (N = 354) were assessed before PRS disclosure (T0), 1 week (T1), and 6 months post-disclosure (T2). PRSs were translated into 10-year and lifetime absolute breast cancer risk estimates. Mixed-effects models were used to test changes in decisional conflict and generalized regression analyses to test PRS effects and interactions with individual characteristics.
resultsDecisional conflict decreased significantly after PRS disclosure. A higher 10-year risk was associated with greater decisional conflict immediately after disclosure. Lifetime risk alone did not predict conflict. Tolerance for ambiguity moderated the effect of lifetime risk at T1: women with lower or medium tolerance experienced higher conflict with high PRSs and lower conflict with low PRSs. Numeracy, age, and family cancer history did not moderate PRS effects.
conclusionDecisional conflict decreased post-PRS disclosure, with short-term responses varying by tolerance for ambiguity, highlighting the importance of tailoring risk communication to patients' psychological characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.